Literature DB >> 25492480

STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma.

Qu Zhang1, Chi Zhang, Jia He, Qing Guo, Desheng Hu, Xi Yang, Jinfeng Wang, Yahui Kang, Ruifang She, Zhongming Wang, Defan Li, Guanhong Huang, Zhaoming Ma, Weidong Mao, Xiaoyi Zhou, Chuangying Xiao, Xinchen Sun, Jianxin Ma.   

Abstract

The radioresistance of esophageal squamous cell carcinoma (ESCC) remains an obstacle for the effective radiotherapy of ESCC. This study aimed to investigate the radiosensitization of ESCC by signal transducer and activator of transcription 3 (STAT3) inhibitor stattic. ECA109, TE13, and KYSE150 cell lines were exposed to hypoxia and treated with stattic or radiation, alone or in combination. Cell proliferation, colony formation, apoptosis, and double-stranded DNA breaks (DSBs) were examined. In addition, ECA109 cells were xenografted into nude mice and treated with radiation and/or stattic. The levels of STAT3, p-STAT3, hypoxia-inducible factor 1α (HIF-1α), and vascular endothelial growth factor (VEGF) in ESCC cells and xenografts were detected by Western blot and immunohistochemical analysis. Our results showed that stattic efficiently radiosensitized ESCC cells and xenografts, especially under hypoxia. Moreover, stattic inhibited STAT3 activation and downregulated HIF-1α and VEGF expression. In conclusion, stattic confers radiosensitivity in ESCC cells in vitro and in vivo and is a potential adjuvant for the radiotherapy of ESCC in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25492480     DOI: 10.1007/s13277-014-2823-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1α in vitro and in vivo.

Authors:  Xi Yang; Baixia Yang; Jing Cai; Chi Zhang; Qu Zhang; Liping Xu; Qin Qin; Hongcheng Zhu; Jianxin Ma; Guangzhou Tao; Hongyan Cheng; Xinchen Sun
Journal:  Cancer Biol Ther       Date:  2013-09-12       Impact factor: 4.742

2.  GRIM-19 inhibits the STAT3 signaling pathway and sensitizes gastric cancer cells to radiation.

Authors:  Xianmin Bu; Chenghai Zhao; Wei Wang; Ning Zhang
Journal:  Gene       Date:  2012-11-01       Impact factor: 3.688

Review 3.  Hypoxia-responsive transcription factors.

Authors:  Eoin P Cummins; Cormac T Taylor
Journal:  Pflugers Arch       Date:  2005-07-09       Impact factor: 3.657

Review 4.  Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression.

Authors:  L Eric Huang; Ranjit S Bindra; Peter M Glazer; Adrian L Harris
Journal:  J Mol Med (Berl)       Date:  2006-12-20       Impact factor: 4.599

5.  HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.

Authors:  Michael J Gray; Jing Zhang; Lee M Ellis; Gregg L Semenza; Douglas B Evans; Stephanie S Watowich; Gary E Gallick
Journal:  Oncogene       Date:  2005-04-28       Impact factor: 9.867

6.  Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.

Authors:  Chao-Yuan Huang; Chen-Si Lin; Wei-Tien Tai; Chi-Ying Hsieh; Chung-Wai Shiau; Ann-Lii Cheng; Kuen-Feng Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-06       Impact factor: 7.038

7.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6.

Authors:  Z Zhong; Z Wen; J E Darnell
Journal:  Science       Date:  1994-04-01       Impact factor: 47.728

8.  Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer.

Authors:  Makoto Sohda; Hitoshi Ishikawa; Norihiro Masuda; Hiroyuki Kato; Tatsuya Miyazaki; Masanobu Nakajima; Minoru Fukuchi; Ryokuhei Manda; Yasuyuki Fukai; Hideyuki Sakurai; Hiroyuki Kuwano
Journal:  Int J Cancer       Date:  2004-07-20       Impact factor: 7.396

Review 9.  Modulating the tumor microenvironment to increase radiation responsiveness.

Authors:  Jayashree Karar; Amit Maity
Journal:  Cancer Biol Ther       Date:  2009-11-03       Impact factor: 4.742

10.  Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.

Authors:  Yunbao Pan; Fuling Zhou; Ronghua Zhang; Francois X Claret
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

View more
  25 in total

1.  IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment.

Authors:  Tatiana A Karakasheva; Eric W Lin; Qiaosi Tang; Edmund Qiao; Todd J Waldron; Monica Soni; Andres J Klein-Szanto; Varun Sahu; Devraj Basu; Shinya Ohashi; Kiichiro Baba; Zachary T Giaccone; Sarah R Walker; David A Frank; E Paul Wileyto; Qi Long; Margaret C Dunagin; Arjun Raj; J Alan Diehl; K K Wong; Adam J Bass; Anil K Rustgi
Journal:  Cancer Res       Date:  2018-07-05       Impact factor: 12.701

2.  TCN, an AKT inhibitor, exhibits potent antitumor activity and enhances radiosensitivity in hypoxic esophageal squamous cell carcinoma in vitro and in vivo.

Authors:  Qing Guo; Jia He; Feng Shen; Wei Zhang; Xi Yang; Chi Zhang; Qu Zhang; Jun-Xing Huang; Zheng-Dong Wu; Xin-Chen Sun; Sheng-Bin Dai
Journal:  Oncol Lett       Date:  2016-12-20       Impact factor: 2.967

3.  Increased radiosensitivity and impaired DNA repair in patients with STAT3-LOF and ZNF341 deficiency, potentially contributing to malignant transformations.

Authors:  Sukru Cekic; Huzeyfe Huriyet; Melika Hortoglu; Nurhan Kasap; Ahmet Ozen; Elif Karakoc-Aydiner; Ayse Metin; Gokhan Ocakoglu; Candan Demiroz Abakay; Sehime G Temel; Sebnem Ozemri Sag; Safa Baris; Tolga Cavas; Sara Sebnem Kilic
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

4.  Delayed Administration of WP1066, an STAT3 Inhibitor, Ameliorates Radiation-Induced Lung Injury in Mice.

Authors:  Jiahua Yu; Xiaopeng Yuan; Yang Liu; Kaishuo Zhang; Jie Wang; Haowen Zhang; Fenju Liu
Journal:  Lung       Date:  2015-11-13       Impact factor: 2.584

5.  Sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway.

Authors:  Yue-Can Zeng; Rui Xing; Jing Zeng; Ming Xue; Feng Chi; Yan Xin; Guo-Liang Fan; Hong-Mei Wang; Qiong-Yu Duan; Yu-Nan Sun; Nan Niu; Rong Wu
Journal:  Tumour Biol       Date:  2015-11-09

Review 6.  Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.

Authors:  Salma K Jabbour; Terence M Williams; Mutlay Sayan; Eric D Miller; Jaffer A Ajani; Andrew C Chang; Norman Coleman; Wael El-Rifai; Michael Haddock; David Ilson; Daniel Jamorabo; Charles Kunos; Steven Lin; Geoffrey Liu; Pataje G Prasanna; Anil K Rustgi; Rosemary Wong; Bhadrasain Vikram; Mansoor M Ahmed
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

Review 7.  Mitochondrial Stat3, the Need for Design Thinking.

Authors:  Rui Yang; Mercedes Rincon
Journal:  Int J Biol Sci       Date:  2016-02-29       Impact factor: 6.580

Review 8.  The tumor microenvironment in esophageal cancer.

Authors:  E W Lin; T A Karakasheva; P D Hicks; A J Bass; A K Rustgi
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

9.  A Novel Biological Activity of the STAT3 Inhibitor Stattic in Inhibiting Glutathione Reductase and Suppressing the Tumorigenicity of Human Cervical Cancer Cells via a ROS-Dependent Pathway.

Authors:  Yuchen Xia; Guihua Wang; Manli Jiang; Xueting Liu; Yan Zhao; Yinghui Song; Binyuan Jiang; Demao Zhu; Ling Hu; Zhao Zhang; Ting Cao; Ji Ming Wang; Jinyue Hu
Journal:  Onco Targets Ther       Date:  2021-07-05       Impact factor: 4.147

10.  CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma.

Authors:  Hongfang Zhang; Jing Yue; Zhenzhen Jiang; Rongjing Zhou; Ruifei Xie; Yiping Xu; Shixiu Wu
Journal:  Cell Death Dis       Date:  2017-05-18       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.